Atara Biotherapeutics (ATRA) Total Liabilities (2013 - 2026)

Atara Biotherapeutics has reported Total Liabilities for 14 years, with the latest figure at $57.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 51.06% year-over-year to $57.3 million; the trailing twelve-month figure through Mar 2026 stood at $57.3 million (down 51.06% YoY), and the FY2025 full-year result was $58.7 million, down 71.54% from the prior year.
• Total Liabilities for Q1 2026 stood at $57.3 million, down from $58.7 million in the prior quarter.
• The five-year high for Total Liabilities was $264.7 million in Q4 2023, with the low at $57.3 million in Q1 2026.
• Historically, Total Liabilities has averaged $180.4 million across 5 years, with a median of $206.4 million in 2024.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 42.62% — and 2025, when it tumbled 71.54%.
• Atara Biotherapeutics' Total Liabilities stood at $249.8 million in 2022, then advanced by 5.99% to $264.7 million in 2023, then fell by 22.04% to $206.4 million in 2024, then plunged by 71.54% to $58.7 million in 2025, then declined by 2.43% to $57.3 million in 2026.
• The last three Total Liabilities figures came in at $57.3 million (Q1 2026), $58.7 million (Q4 2025), and $66.8 million (Q3 2025), per Business Quant data.